Meta-analysis of 19 studies (2,780 patients) after CAR T-cell therapy: pooled HLH incidence was 1.6% with HLH mortality 0.7%; incidence was highest in B-ALL (6.9%) and varied by product, being highest with tisagenlecleucel (4.3%).
Meta-analysisn = 2,780
Zhang et al. Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis